At a Toronto cancer centre, researchers are asking whether a vial of blood might one day quiet the deepest fear a cancer survivor carries — the fear that the illness never truly left. The SHERLOCK trial, enrolling 7,000 patients at Princess Margaret Cancer Centre, is testing liquid biopsy technology capable of detecting tumour DNA fragments too small for conventional imaging to find, potentially allowing doctors to intervene before recurrence becomes visible or to offer patients the rare gift of genuine certainty. It is a methodical, years-long undertaking, grounded in the understanding that m
CP24 Toronto
· Jul 08, 2026
· health
· 4 min read
High
Sourcing: Verified
Blood test could detect cancer recurrence before CT scans, Toronto researchers find
Cancer patients experience significant psychological burden from fear of recurrence during follow-up appointments, which this blood test could potentially alleviate.
◉
Health & Medicine
8412 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
🌎
Canadian cancer research advances medical technology; no direct geopolitical implications identified in this healthcare innovation article.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Toronto researchers are conducting a large-scale trial testing blood tests to detect microscopic cancer DNA after treatment, potentially enabling earlier intervention and reducing unnecessary treatments, with significant implications for oncology diagnostics and pharmaceutical markets.
Market Signal
bullish
Confidence
HIGH
Healthcare/Oncology
Diagnostic Testing/Laboratory Services
Pharmaceutical/Immunotherapy
Medical Devices
Health Insurance
Hospital/Cancer Treatment Centers
Patients could benefit from earlier cancer recurrence detection, reduced unnecessary chemotherapy/radiation side effects, and improved treatment outcomes. However, costs of liquid biopsy tests and new immunotherapies may increase out-of-pocket expenses depending on insurance coverage.
Regulatory bodies (Health Canada, FDA) will need to establish approval pathways for liquid biopsy tests as standard of care. Healthcare systems may need to integrate blood testing into post-treatment protocols, potentially increasing diagnostic budgets. Insurance coverage policies will need updating to determine reimbursement for preventive liquid biopsies and follow-up immunotherapies.